Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1993-08-24
1996-09-24
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
43524027, 4241411, 4241301, 4241391, 53038835, 5303879, 5303881, 5303871, C12N 512, A61K 3942, C07K 1612
Patent
active
055588654
ABSTRACT:
The present invention provides monoclonal antibodies that are specifically immunoreactive with an HIV-1 gp120 protein or its precursor gp160 protein comprising the amino acid sequence set out in SEQ ID NO: 1, G-P-G-R, and characterized by their ability to neutralize, in vitro, the infection of H9 cells by live HIV-1 strains MN and III.sub.B as determined by reverse transcriptase, p24, MT-2 and syncytium formation assays. Presently preferred antibody NM-01 isolated from mouse/mouse hybridoma ATCC HB 10726 is further characterized by its capacity to mediate complement-dependent virolysis of HIV-1 particles and antibody-dependent cellular cytotoxicity of HIV-1 infected cells. Antibodies consisting essentially of a human antibody variable region comprising a sequence of amino acids of at least one complementarity determining region of the monoclonal antibody produced by the hybridoma cell line ATCC HB 10726 are specifically disclosed. Pharmaceutical compositions of the invention are projected to be useful in the passive immunization treatment of animals, especially humans, susceptible to or infected with HIV-1.
REFERENCES:
patent: 5019387 (1991-05-01), Haynes et al.
Akerblom et al., "Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp 120", AIDS, 4: 953-960 (1990).
Banapour et al., "The AIDS-Associated Retrovirus is Not Sensitive to Lysis or Inactivation by Human Serum", Virology, 152: 268-271 (1986).
Bartholomew et al., "Lysis of Oncornaviruses by Human Serum", J. Exp. Med., 147: 844-853 (1978).
Broliden et al., "Identification of Amino Acids in the V3 Region of gp120 for Virus Neutralization by HIV-1 Specific Antibodies," Immunology, 73: 371-376 (1991).
Cheng-Mayer et al., "Human Immunodeficiency Virus Can Productively Infect Cultured Human Glial Cells", Proc. Natl. Acad. Sci., USA, 84: 3526-3530 (1987).
Chothia et al., "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol., 196: 901-917 (1987).
Cooper et al., "Lysis of RNA Tumor Viruses by Human Serum: Direct Antibody-Independent Triggering of the Classical Complement Pathway", J. Exp. Med., 144: 970-984 (1976).
Durda et al., "HIV-1 Neutralizing Monoclonal Antibodies Induced by a Synthetic Peptide", AIDS Res. Human Restrov., 6: 1115-1123 (1990).
Emini et al., "Prevention of HIV-1 Infection in Chimpanzees by gp120 V3 Domain-Specific Monoclonal Antibody", Nature, 355: 728-730 (1992).
Epp et al., "Crystal and Molecular Structure of a Dimer Composed of the Variable Portions of the Bence-Jones Protein REI", Eur J. Biochem, 45: 513-524 (1974).
Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops", J. Mol. Biol., 224: 487-499 (1992).
Fung et al., "Monoclonal Antibodies that Neutralize HIV-1 Virions and Inhibit Syncytium Formation by Infected Cells", Bio/Technology, 5:940-946 (1987).
Goding, "Antibody Production by Hybridomas", J. Immunol. Meth. 39: 285-308 (1980).
Gorny et al., "Production of Site-Selected Neutralizing Human Monoclonal Antibodies Against the Third Variable Domain of the Human Immunodeficiency Virus Type 1 Envelope glycoprotein", Proc. Natl. Acad. Sci., USA, 88: 3238-3242 (1991).
Gorny et al., "Neutralization of Diverse Human Immunodeficieny Virus Type 1 Variants by an Anti-V3 Human Monoclonal Antibody,"J. Virol., 66(12): 7538-7542 (Dec. 1992).
Goudsmit et al., "Human Immunodeficiency Virus Type 1 Neutralization Epitome With Conserved Architecture Elicits Early Type-Specific Antibodies in Experimentally Infected Chimpanzees", Proc. Natl. Acad. Sci., USA, 85: 4478-4482 (1988).
Haigwood et al., "Evidence for Neutralizing Antibodies Directed Against Conformational Epitopes of HIV-1 gp120",Vaccines, 90: 313-320 (1990).
Halstead et al., "Antibody-Enhanced Dengue Virus Infection in Primate Leukocytes", Nature 265: 739-741 (1977).
Ho et al., "Conformational Epitope on gp120 Important in CD4 Binding and Human Immunodeficiency Virus Type 1 Neutralization Identified by a Human Monoclonal Antibody", J. Virol. 65(1): 489-493 (1991).
Ho et al., "Second Conserved Domain of gp120 Is Important for HIV Infectivity and Antibody Neutralization", Science, 239: 1021-1023 (1988).
Holley et al., "Prediction of Optimal Peptide Mixtures to Induce Broadly Neutralizing Antibodies to Human Immunodeficiency Virus Type 1",Proc. Natl. Acad. Sci., USA, 88: 6800-6804 (1991).
Jackson et al., "Passive Immunoneutralisation of Human Immunodeficiency Virus in Patients with Advanced AIDS", The Lancet: 647-652 (1988).
Javaherian et al., "Principal Neutralizing Domain of the Human Immunodeficiency Virus Type 1 Envelope Protein", Proc. Natl. Acad. Sci., USA, 86: 6768-6772 (1989).
Javaherian et al., "Broadly Neutralizing Antibodies Elicited by the Hypervariable Neutralizing Determinant of HIV-1", Science, 250: 1590-1593 (1990).
Johnson et al., "HIV-Infected Cell Fusion Assay" Techniques in HIV-1 Research, Techniques in HIV-1 Research, Stockton Press, New York pp. 92-97 (1990).
Kabat et al., "Sequences of Proteins of Immunological Interest," 5th Edition, U.S. Department of Health and Human Services, U.S. Government Printing Office (1991).
Karpas et al., "Effects of Passive Immunization in Patients with the Acquired Immunodeficiency Syndrome-Related Complex and Acquired Immunodeficiency Syndrome", Proc. Natl. Acad. Sci., USA, 85: 9234-9237 (1988).
LaRosa et al., "Conserved Sequence and Structural Elements in the HIV-1 Principal Neutralizing Determinant", Science, 249: 932-935 (1990).
Lasky et al., "Neutralization of the AIDS Retrovirus by Antibodies to a Recombinant Envelope Glycoprotein", Science, 233: 209-212 (1986).
Liou et al., "A Chimeric Mouse-Human Antibody that Retains Specificity for HIV gp120 and Mediates the Lysis of HIV-Infected Cells", J. of Immun., 143(12): 3967-3975 (1989).
Matsushita et al., "Characterization of a Human Immunodeficiency Virus Neutralizing Monoclonal Antibody and Mapping of the Neutralizing Epitope", J. Virol., 62: 2107-2114 (1988).
McCune, "HIV-1: The Infective Process in Vivo", Cell, 64: 351-363 (1991).
Mosmann, "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays", J. Immunol Meth., 65: 55-63 (1983).
Nakamura et al., "Complement-Dependent Virolysis of HIV-1 with Monoclonal Antibody NM-01" AIDS Research and Human Retroviruses, 9(7):619-626 (1993).
Ohno et al., "A broadly neutralizing monoclonal antibody that recognizes the V.sub.3 region of human immunodeficiency virus type 1 glycoprotein gp120", Proc. Natl. Acad. Sci. USA, 88:10726-10729 (Dec. 1991).
Oi et al., "Immunoglobulin-Producing Hybrid Cell Lines", Selected Methods Cell Immunology, pp. 351-372 (1979).
Orlandi et al., "Cloning Immunoglobulin Variable Domains for Expression by the Po;ymerase Chain Reaction", Proc. Natl. Acad. Sci., USA, 86: 3833-3837 (1989).
Palker et al., "Type-specific Neutralization of the Human Immunodeficiency Virus with Antibodies to Env-encoded Synthetic Peptides", Proc. Natl. Acad. Sci., USA, 85: 1932-1936 (1988).
Pauwels et al., "Rapid and Automated Tetrazolium-Based Colorimetric Assay for the Detection of Anti-HIV Compounds", J. Virol Meth., 20: 309-321 (1988).
Peiris et al., "Monoclonal Anti-Fc Receptor IgG Blocks Antibody Enhancement of Viral Replication in Macrophages", Nature, 289: 189-191 (1981).
Pirofski et al., "Variable Region Gene Utilization and Mutation in a Group of Neutralizing Murine Anti-Human Immunodeficiency Virus Type I Principal Neutralizing Determinant Antibodies", AIDS Research and Human Retroviruses, 9(1):41-49 (1993).
Poiesz et al., "Detection and Isolation of Type C Retrovirus Particles from Fresh and Cultured Lymphocytes of a Patent with Cutaneous T-Cell Lymphoma", Proc. Natl. Sci., USA, 77: 7415-7419 (1980).
Putney et al., "HTLV-III/LAV-Neutralizing Antibodies to an E. Coli-Produced Fragment of the Virus Envelope", Science,234: 1392-1395 (1986).
Richman, "Plaque Reduction and Cytotoxicity Assays of HIV Sensitivity to Antiviral Compounds", AIDS Research and Reference Reagent Program, Courier No. 90-01, pp. 6-9 (1990).
Riechmann et al., "Reshaping Human Anti
Feisee Lila
Nissin Shokuhin Kabushiki Kaisha
LandOfFree
HIV immunotherapeutics does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with HIV immunotherapeutics, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV immunotherapeutics will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1927132